Replimune Group, Inc. (NASDAQ:REPL) Receives $4.88 Average Price Target from Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been given an average recommendation of “Reduce” by the ten analysts that are covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation and seven have assigned a hold recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $4.8750.

Several equities research analysts have commented on REPL shares. Leerink Partners reissued a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. Wedbush upped their target price on shares of Replimune Group from $2.00 to $6.00 and gave the company a “neutral” rating in a report on Monday, June 1st. JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $8.00 target price on the stock in a report on Friday, May 29th. Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Friday, April 10th. Finally, Cantor Fitzgerald cut shares of Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th.

Replimune Group Trading Up 3.0%

Shares of NASDAQ:REPL opened at $8.88 on Wednesday. The company’s 50-day moving average price is $5.25 and its two-hundred day moving average price is $7.27. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. Replimune Group has a one year low of $1.50 and a one year high of $13.24. The stock has a market capitalization of $733.22 million, a PE ratio of -2.58 and a beta of 0.91.

Insider Activity

In other news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the sale, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently modified their holdings of the company. RTW Investments LP raised its holdings in shares of Replimune Group by 11.6% in the 4th quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock valued at $69,404,000 after purchasing an additional 744,620 shares during the period. Fcpm Iii Services B.V. raised its holdings in shares of Replimune Group by 6.4% in the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock valued at $17,424,000 after purchasing an additional 248,672 shares during the period. State Street Corp grew its stake in Replimune Group by 26.3% in the 4th quarter. State Street Corp now owns 3,693,107 shares of the company’s stock valued at $35,897,000 after buying an additional 768,982 shares during the last quarter. Vanguard Group Inc. raised its holdings in Replimune Group by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock valued at $14,579,000 after acquiring an additional 9,707 shares during the period. Finally, Braidwell LP raised its holdings in Replimune Group by 550.3% in the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after acquiring an additional 2,327,205 shares during the period. 92.53% of the stock is owned by institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.